Latest Breaking News On - மேதாண்த நிறுவனம் ஆஃப் கல்வி - Page 1 : comparemela.com

Date Time Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India – one of the world’s most ethnically diverse countries. Researchers from the University of Bristol and Medanta Institute of Education and Research in India who led the study, published in The Lancet Respiratory Medicine, say it adds to existing evidence supporting the drug’s use in critically ill patients. Conducted in 12 public and private hospitals across India, the COVID India Tocilizumab (COVINTOC) phase 3 randomised controlled trial aimed to investigate whether tocilizumab could prevent disease progression and mortality in hospitalised patients with moderate to severe COVID-19.

Bristol
City-of
United-kingdom
United-states
India
America
Arvinder-soin
Arvinders-soin
University-of-bristol-medical-school
Medanta-institute-of-education
Medanta-liver-transplantation-institute-at-gurugram
University-of-bristol